Brief: ARCA biopharma Reports Enrollment of First International Patient in Trial Evaluating rNAPc2 as Potential Treatment for COVID-19

Oruka Therapeutics

16/09/2021 13:49

Sept 16 (Reuters) - ARCA Biopharma Inc  ABIO.O :
    * ARCA BIOPHARMA ANNOUNCES ENROLLMENT OF FIRST INTERNATIONAL
PATIENT IN PHASE 2B CLINICAL TRIAL EVALUATING RNAPC2 AS A
POTENTIAL TREATMENT FOR COVID-19
    * ARCA BIOPHARMA INC - TOPLINE TRIAL DATA ANTICIPATED IN Q4
OF
2021
    * ARCA BIOPHARMA - INTERNATIONAL PHASE 2B TRIAL IS ABOUT 75%
ENROLLED AS OF THIS DATE

Source text for Eikon:  ID:nGNX4kxHvF 
Further company coverage:  ABIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))